[{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Bill & Melinda Gates Foundation \/ The Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ The Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Antiviral drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Inventprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"IVT-25","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Atreca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"ATRC-501","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Medical Research Institute"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Gritstone bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Self-Amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Anti-CSP IgM Antibodies","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Vaccinal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"DprE1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bactolife","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Nuvisan GmbH","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"DARE-LBT","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Norovirus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Smart Immune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Allogeneic T-cell Progenitor","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"VIR-1388","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"DNA-encoded Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"AS01E","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.55000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Delamanid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"VitriVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Sail Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Aegis Life","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"MTBVAC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bill & Melinda Gates Foundation","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Surf Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"SNIPR Biome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Ethris","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Radiant Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bill & Melinda Gates Foundation","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Chemify","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Immorna","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"JCXH-108","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"PopVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bill & Melinda Gates Foundation","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"14","companyTruncated":"Bill & Melinda Gates Foundation \/ Bill & Melinda Gates Foundation"}]

Find Clinical Drug Pipeline Developments & Deals by Bill & Melinda Gates Foundation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will fund the development to accelerate the ongoing Ovaprene (ferrous gluconate & ascorbic acid), a novel, hormone-free monthly intravaginal contraceptive, pivotal study.

                          Brand Name : Ovaprene

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Recipient : Daré Bioscience

                          Deal Size : $10.7 million

                          Deal Type : Funding

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will be used to develop novel thermostable delivery formulations for mRNA-based vaccines and therapeutics.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 30, 2024

                          Lead Product(s) : mRNA-based Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : PopVax

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding will aims to support the company to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : AN2 Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding will support the efficient design and synthesis of novel small molecules for treating TB and malaria by leveraging the company’s proprietary Chemputation technology and workflow.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 01, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : Chemify

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : This financing will enable the next stage in Radiant’s growth and move the company toward the clinic, Multabody platform against therapeutic targets that cannot be treated with traditional antibodies.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 11, 2024

                          Lead Product(s) : Antibody-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Radiant Biotherapeutics

                          Deal Size : $35.0 million

                          Deal Type : Series A Financing

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding aims to advance the clinical development of JCXH-108, which is a monovalent RSV vaccine being developed by Immorna using its proprietary mRNA and RTU-LNP technologies.

                          Brand Name : JCXH-108

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 26, 2024

                          Lead Product(s) : JCXH-108

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Recipient : Immorna

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Recipient : SNIPR Biome

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding aims to support the company first-in-class mRNA-based product candidate ETH47, which is being evaluated in the early-stage clinical trial studies for the treatment of asthma.

                          Brand Name : ETH47

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 18, 2024

                          Lead Product(s) : ETH47

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Ethris

                          Deal Size : $5.0 million

                          Deal Type : Funding

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding will evaluate the use of the company’s technology toward increasing the thermostability of a monoclonal antibody to develop therapies for oncology and autoimmune diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 30, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Surf Bio

                          Deal Size : $1.6 million

                          Deal Type : Funding

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Proceeds will support Aegis Life and Entos Pharmaceuticals' collaboration on DNA-based antibody therapeutics against HIV and malaria.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 19, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Aegis Life

                          Deal Size : $4.4 million

                          Deal Type : Financing

                          blank